GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects

被引:70
作者
Klabunde, T [1 ]
Evers, A [1 ]
机构
[1] Aventis Pharma Deutschland GmbH, Sanofi Aventis Grp, Sci & Med Affairs Drug Design, D-65926 Frankfurt, Germany
关键词
amines; drug design; G protein-coupled receptors; pharmacophore modeling; structure-activity relationships;
D O I
10.1002/cbic.200400369
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
G protein-coupled receptors (GPCRs) form a large protein family that plays an important role in many physiological and pathophysiological processes. However, the central role that the biogenic amine binding GPCRs and their ligands play in cell signaling poses a risk in new drug candidates that reveal side affinities towards these receptor sites. These candidates have the potential to interfere with the physiological signaling processes and to cause undesired effects in preclinical or clinical studies. Here, we present 3D cross-chemotype pharmacophore models for three biogenic amine antitargets: the a(1A) adrenergic, the 5-HT2A serotonin, and the D2 dopamine receptors. These pharmacophores describe the key chemical features present within these biogenic amine antagonists and rationalize the biogenic amine side affinities found for numerous new drug candidates. First applications of the alpha(1A) odrenergic receptor model reveal that these in silica tools can be used to guide the chemical optimization towards development candidates with fewer alpha(1A)-mediated side effects (for example, orthostatic hypotension) and, thus, with an improved clinical safety profile.
引用
收藏
页码:876 / 889
页数:14
相关论文
共 44 条
[1]  
*ACC INC, 2002, CAT VERS 4 7
[2]   Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward α1- and α2-adrenoceptors [J].
Barbaro, R ;
Betti, L ;
Botta, M ;
Corelli, F ;
Giannaccini, G ;
Maccari, L ;
Manetti, F ;
Strappaghetti, G ;
Corsano, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (13) :2118-2132
[3]   Phenylpiperazinylalkylamino substituted pyridazinones as potent α1 adrenoceptor antagonists [J].
Barlocco, D ;
Cignarella, G ;
Dal Piaz, V ;
Giovannoni, MP ;
De Benedetti, PG ;
Fanelli, F ;
Montesano, F ;
Poggesi, E ;
Leonardi, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (15) :2403-2410
[4]  
BARON B, 2004, COMMUNICATION
[5]   THE PHARMACOLOGY AND DISTRIBUTION OF HUMAN 5-HYDROXYTRYPTAMINE(2B) (5-HT2B) RECEPTOR GENE-PRODUCTS - COMPARISON WITH 5-HT2A AND 5-HT2C RECEPTORS [J].
BONHAUS, DW ;
BACH, C ;
DESOUZA, A ;
SALAZAR, FHR ;
MATSUOKA, BD ;
ZUPPAN, P ;
CHAN, HW ;
EGLEN, RM .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (04) :622-628
[6]   Ligand design for alpha, adrenoceptors [J].
Bremner, JB ;
Griffith, R ;
Coban, B .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (06) :607-620
[7]   alpha(1)-adrenoceptor-induced contractility in rat aorta is mediated by the alpha(1D) subtype [J].
Buckner, SA ;
Oheim, KW ;
Morse, PA ;
Knepper, SM ;
Hancock, AA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 297 (03) :241-248
[8]   A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor [J].
Chambers, JJ ;
Nichols, DE .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (07) :511-520
[9]   Structure-based drug discovery using GPCR homology modeling: Successful virtual screening for antagonists of the Alpha1A adrenergic receptor [J].
Evers, A ;
Klabunde, T .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :1088-1097
[10]   Pharmacological pleiotropism of the human recombinant alpha(1A)-adrenoceptor: implications for alpha(1)-adrenoceptor classification [J].
Ford, APDW ;
Daniels, DV ;
Chang, DJ ;
Gever, JR ;
Jasper, JR ;
Lesnick, JD ;
Clarke, DE .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (06) :1127-1135